Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. News
  7. Summary
    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Delayed Nasdaq Copenhagen  -  10:59 2022-11-29 am EST
879.90 DKK   +2.50%
11/25NOVO NORDISK : Berenberg reaffirms its Neutral rating
MD
11/23Eurozone PMI Data Supports European Equities
MT
11/22The technical configuration is positive
MS
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Days
:
Hours
:
Minutes
:
Seconds

Novo Nordisk Enters Exclusive Worldwide License Agreement With Ventus Therapeutics

09/29/2022 | 09:05am EST


ę MT Newswires 2022
All news about NOVO NORDISK A/S
11/25NOVO NORDISK : Berenberg reaffirms its Neutral rating
MD
11/23Eurozone PMI Data Supports European Equities
MT
11/22Novo Nordisk Invests $743.6 Million to Expand Clinical Manufacturing Facilities
DJ
11/22Drug maker Novo Nordisk invests $744 million to expand Danish plant
RE
11/22Novo Nordisk to Spend $744 Million to Expand Clinical Active Pharma Ingredients Capacit..
MT
11/22Novo Nordisk invests DKK 5.4 bn Danish kroner in expansion of clinical manufacturing fa..
GL
11/22Novo Nordisk invests DKK 5.4 bn Danish kroner in expansion of clinical manufacturing fa..
GL
11/22Novo Nordisk Invests DKK 5.4 billion Danish Kroner in Expansion of Clinical Manufacturi..
CI
11/21Novo Nordisk Agrees to $40 Million Milestone Payment to Prothena
MT
11/21Prothena Achieves $40 Million Clinical Milestone Payment From Novo Nordisk
DJ
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Financials
Sales 2022 175 B 24 370 M 24 370 M
Net income 2022 55 086 M 7 659 M 7 659 M
Net Debt 2022 4 710 M 655 M 655 M
P/E ratio 2022 36,1x
Yield 2022 1,34%
Capitalization 1 989 B 276 B 276 B
EV / Sales 2022 11,4x
EV / Sales 2023 9,87x
Nbr of Employees 52 696
Free-Float 75,0%
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 879,90 DKK
Average target price 865,72 DKK
Spread / Average Target -1,61%
EPS Revisions
Managers and Directors
Lars Fruergaard J°rgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Henrik Ehlers Wulff Senior Vice President-Diabetes API
Stephen Gough Global Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVO NORDISK A/S16.79%270 881
JOHNSON & JOHNSON3.66%463 626
ELI LILLY AND COMPANY32.23%347 547
ABBVIE INC.17.01%280 085
PFIZER, INC.-16.05%278 252
MERCK & CO., INC.41.51%274 964